Sotatercept
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pulmonary Arterial Hypertension PAH
Conditions
Pulmonary Arterial Hypertension PAH, Pulmonary Arterial Hypertension WHO Group I, Pulmonary Arterial Hypertension
Trial Timeline
May 14, 2025 → May 1, 2026
NCT ID
NCT06658522About Sotatercept
Sotatercept is a approved stage product being developed by Merck for Pulmonary Arterial Hypertension PAH. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06658522. Target conditions include Pulmonary Arterial Hypertension PAH, Pulmonary Arterial Hypertension WHO Group I, Pulmonary Arterial Hypertension.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07140484 | Approved | Recruiting |
| NCT06658522 | Approved | Recruiting |
| NCT06814145 | Phase 2 | Recruiting |
| NCT06843460 | Phase 1 | Completed |
| NCT05818137 | Phase 3 | Completed |
| NCT05587712 | Phase 2 | Recruiting |
| NCT04811092 | Phase 3 | Completed |
| NCT04896008 | Phase 3 | Completed |
| NCT07218029 | Phase 3 | Recruiting |
| NCT03738150 | Phase 2 | Completed |
| NCT01736683 | Phase 2 | Completed |
| NCT01190644 | Phase 2 | Terminated |
Competing Products
20 competing products in Pulmonary Arterial Hypertension PAH